The potential of hyperpolarized ¹³C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents

References

• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423–435.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520–11539.
   PubMed Web of Science ®Google Scholar
• Clemenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol. 2013;86:143–160.
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res. 2006;12:4090–4094.
   PubMed Web of Science ®Google Scholar
• Folkes LK, Christlieb M, Madej E, et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol. 2007;20:1885–1894.
   PubMed Web of Science ®Google Scholar
• Iversen AB, Busk M, Horsman MR. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol. 2013;52:1320–1326.
   PubMed Web of Science ®Google Scholar
• Neves AA, Brindle KM. Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta. 2006;1766:242–261.
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. JCO. 2003;21:2831–2842.
   PubMed Web of Science ®Google Scholar
• Anderson HL, Yap JT, Miller MP, et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003;21:2823–2830.
   PubMed Web of Science ®Google Scholar
• O'connor JP, Jackson A, Asselin MC, et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol. 2008;9:766–776.
   PubMed Web of Science ®Google Scholar
• Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282–3292.
   PubMed Web of Science ®Google Scholar
• Sengupta D, Pratx G. Imaging metabolic heterogeneity in cancer. Mol Cancer. 2016;15:4.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2007;72:226–233.
   PubMed Web of Science ®Google Scholar
• Phelps ME, Mazziotta JC. Positron emission tomography: human brain function and biochemistry. Science. 1985;228:799–809.
   PubMed Web of Science ®Google Scholar
• Serrao EM, Brindle KM. Potential clinical roles for metabolic imaging with hyperpolarized [1-(13)C]pyruvate. Front Oncol. 2016;6:59.
   PubMed Web of Science ®Google Scholar
• Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158–10163.
   PubMed Web of Science ®Google Scholar
• Golman K, In'T Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci USA. 2006;103:11270–11275.
   PubMed Web of Science ®Google Scholar
• Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med. 2013;5:198ra108.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980;6:1507–1517.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Ehrnrooth E, Ladekarl M, et al. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys. 1998;42:895–898.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Wittenborn T, Horsman MR. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in preclinical studies of antivascular treatments. Pharmaceutics. 2012;4:563–589.
   PubMedGoogle Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol. 2001;77:195–204.
   PubMed Web of Science ®Google Scholar
• Busk M, Munk OL, Jakobsen S, et al. FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach. Acta Oncol. 2017;56:706–712.
   PubMed Web of Science ®Google Scholar
• Bohndiek SE, Kettunen MI, Hu DE, et al. Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy. Mol Cancer Ther. 2010;9:3278–3288.
   PubMed Web of Science ®Google Scholar